Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | HTR2A | P28223 | 3/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 2/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3581330 | 0.94 | MAOA (0.48) | MAOASIGMAR1HTR2ACYP2A6SMN1; SMN2 | |
| SCHEMBL3589419 | 0.92 | MAOA (0.47) | MAOASIGMAR1HRH1 | |
| SCHEMBL3584588 | 0.92 | MAOA (0.47) | MAOASIGMAR1HRH1 | |
| SCHEMBL3584831 | 0.92 | MAOA (0.47) | MAOASIGMAR1HRH1 | |
| SCHEMBL3593183 | 0.92 | MAOA (0.47) | MAOASIGMAR1HRH1 | |
| SCHEMBL3587599 | 0.92 | MAOA (0.47) | MAOASIGMAR1HRH1 | |
| SCHEMBL3588310 | 0.92 | MAOA (0.47) | MAOASIGMAR1HRH1 | |
| SCHEMBL3596268 | 0.92 | MAOA (0.47) | MAOASIGMAR1HRH1 | |
| SCHEMBL3587172 | 0.92 | MAOA (0.47) | MAOASIGMAR1HRH1 | |
| SCHEMBL3593093 | 0.92 | MAOA (0.47) | MAOASIGMAR1HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 738 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024031596-A1 | COMPOSITION FOR TREATING KERATIN FIBERS | L'OREAL (FR) | 2024-02-15 | — | — | WO | claimed |
| US-20230174509-A1 | THERAPEUTIC USE OF PLEUROMUTILINS | ARIVA MED GMBH (AT) | 2023-06-08 | — | — | US | claimed |
| EP-4188316-A1 | HAIR COSMETIC COMPOSITIONS FOR PRESERVING OR MAINTAINING THE STYLE OR SHAPE OF HAIR | L'OREAL (FR) | 2023-06-07 | — | — | EP | claimed |
| EP-4135683-A1 | THERAPEUTIC USE OF PLEUROMUTILINS | Nabriva Therapeutics GMBH (AT) | 2023-02-22 | — | — | EP | claimed |
| CN-115413238-A | Therapeutic use of pleuromutilin compounds | 纳布里瓦治疗有限责任公司 | 2022-11-29 | — | — | CN | claimed |
| WO-2022146720-A1 | COSMETIC AND PERSONAL CARE COMPOSITIONS CONTAINING CATIONIC SURFACTANTS AND ANIONIC COMPOUNDS | L'OREAL (FR) | 2022-07-07 | — | — | WO | claimed |
| CN-114685968-A | Damp-heat-resistant polycarbonate composition and preparation method and application thereof | 金发科技股份有限公司 | 2022-07-01 | — | — | CN | claimed |
| US-20220202686-A1 | COSMETIC AND PERSONAL CARE COMPOSITIONS CONTAINING CATIONIC SURFACTANTS AND ANIONIC COMPOUNDS | L'OREAL (FR) | 2022-06-30 | — | — | US | claimed |
| US-20220202674-A1 | COSMETIC AND PERSONAL CARE COMPOSITIONS CONTAINING CATIONIC SURFACTANTS AND ANIONIC COMPOUNDS | L'OREAL (FR) | 2022-06-30 | — | — | US | claimed |
| WO-2022026790-A1 | HAIR COSMETIC COMPOSITIONS FOR PRESERVING OR MAINTAINING THE STYLE OR SHAPE OF HAIR | L'OREAL (FR) | 2022-02-03 | — | — | WO | claimed |
| WO-2006065511-A2 | AESTHETIC, STABLE CHROMATIC EMULSIONS | AVON PRODUCTS, INC. (US) | 2006-06-22 | — | — | WO | claimed |
| US-20060128883-A1 | Aesthetic, stable chromatic emulsions | AVON PRODUCTS, INC. | 2006-06-15 | — | — | US | claimed |
| CN-1281362-A | Novel combination medicine | ASTRA ZENECA BRITISH CO LTD (GB) | 2001-01-24 | — | — | CN | claimed |
| EP-1027052-A1 | NOVEL COMBINATION | AstraZeneca UK Limited (GB) | 2000-08-16 | — | — | EP | claimed |
| US-6063789-A | Aminoisoquinolines and aminotheinopyridine derivatives and their use as anti-inflammatory agents | ASTRA PHARMACEUTICALS, LTD. (GB) | 2000-05-16 | — | — | US | claimed |
| US-6046191-A | PHARMACEUTICAL COMBINATION COMPRISING A COX-2 INHIBITOR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND AN AMIDINE COMPOUND; FOR TREATMENT OF INFLAMMATORY DISORDERS | ASTRA PHARMACEUTICALS LTD. (GB) | 2000-04-04 | — | — | US | claimed |
| CN-1221407-A | Aminoisoquinolines and aminothienopyridine derivatives and their use as anti-inflammatory agents | ASTRA PHARMA PROD (GB) | 1999-06-30 | — | — | CN | claimed |
| WO-1999018960-A1 | NOVEL COMBINATION | ASTRAZENECA UK LIMITED (GB) | 1999-04-22 | — | — | WO | claimed |
| EP-0892784-A1 | AMINOISOQUINOLINES AND AMINOTHIENOPYRIDINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | Astra Pharmaceuticals Limited (GB) | 1999-01-27 | — | — | EP | claimed |
| WO-1997038977-A1 | AMINOISOQUINOLINES AND AMINOTHIENOPYRIDINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | ASTRA PHARMACEUTICALS LTD. (GB) | 1997-10-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220202686-A1 | COSMETIC AND PERSONAL CARE COMPOSITIONS CONTAINING CATIONIC SURFACTANTS AND ANIONIC COMPOUNDS | CUTA, SGMS1, PHOSPHO1 | MAOA 2918/4885SIGMAR1 1107/4885HTR2A 2328/4885 |
| US-20220202674-A1 | COSMETIC AND PERSONAL CARE COMPOSITIONS CONTAINING CATIONIC SURFACTANTS AND ANIONIC COMPOUNDS | SGMS1, MITF, SGMS2 | MAOA 3519/4885SIGMAR1 2151/4885HTR2A 3515/4885 |
| US-20230174509-A1 | THERAPEUTIC USE OF PLEUROMUTILINS | MLN, PLEC, PELP1 | MAOA 1431/4885SIGMAR1 3062/4885HTR2A 1669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.